bioRxivBiochemistryPreprint
ALTering cancer by triggering telomere replication stress through the stabilization of promoter G-quadruplex in SMARCAL1
S. Panda, T. Roychowdhury, A. Dutta, S. Chakraborty, T. Das, S. Chatterjee
Abstract
Most of the human cancers are dependent on telomerase to extend the telomeres. But [~]10% of all cancers use a telomerase-independent, homologous recombination mediated pathway called alternative lengthening of telomeres (ALT). Due to poor prognosis, the ALT status is not being considered yet in the diagnosis of cancer. No such specific treatment is available till date for ALT cancers. ALT positive cancers are dependent on replication stress to deploy DNA repair pathways to the telomeres to execute homology recombination mediated telomere extension. SMARCAL1 (SWI/SNF related, matrix-associated, actin-dependent regulator of chromatin, subfamily A-like 1) is associated with the ALT telomeres to resolve replication stress thus providing telomere stability. Thus, the dependency on replication stress regulatory factors like SMARCAL1 made it a suitable therapeutic target for the treatment of ALT positive cancers. In this study, we found a significant downregulation of SMARCAL1 expression by stabilizing the G-quadruplex (G4) motif found in the promoter of SMARCAL1 by potent G4 stabilizers, like TMPyP4 and BRACO-19. SMARCAL1 downregulation led towards the increased localization of PML (promyelocytic leukaemia) bodies in ALT telomeres and triggered the formation of APBs (ALT-associated promyelocytic leukaemia bodies) in ALT positive cell lines, thus increasing telomere replication stress and DNA damage at genomic level. Induction of replication stress and hyper recombinogenic phenotype in ALT cells mediated by G4 stabilizing molecules already highlighted their possible application as a new therapeutic window to target ALT-positive tumors. In accordance with this, our study will also provide a valuable insight towards the development of G4 based ALT-therapeutics targeting SMARCAL1.
- organism: human
- assay: DNA methylation
- assay: proteomics
- research focus: cancer & tumor microenvironment
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells
H. Liu, C. Xu, … M. S. Waitkus·bioRxiv·Sep 19, 2022
- Tabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers
Declan Bennett, Monika Wierdl, … Lillian M. Guenther·bioRxiv·May 28, 2026
- SMARCAL1 is a candidate therapeutic target for ALT-positive tumors
Angelo Taglialatela, Jina Lee, … Alberto Ciccia·bioRxiv·Feb 16, 2026
- Human PC4 supports telomere stability and viability in cells utilizing the alternative lengthening of telomeres mechanism
Sara Salgado, Patrícia L. Abreu, … Claus M. Azzalin·EMBO ReportsPeer-reviewed·Oct 28, 2024
- The Single-Stranded DNA-Binding Factor SUB1/PC4 Alleviates Replication Stress at Telomeres and is a Vulnerability of ALT Cancer Cells
Jean-Christophe Dubois, Erin Bonnell, … Alexandre Maréchal·Proceedings of the National Academy of SciencesPeer-reviewed·Jan 7, 2025
- SLX4IP acts in parallel to FANCM to limit BLM-dependent replication stress at ALT telomeres
Jessica Spindler, Francesca Pandolfo, … Stephanie Panier·bioRxiv·May 28, 2025